As shown in Supplementary Figure S2, a high expression of MYO15B (P=0.003), GIGYF1 (P=0.009), TRAF3IP3 (P=0.013), RBM6 (P=0.025), PABPN1 (P=0.014), FAM118A (P=0.036), and CCNL1 (P=0.014) was associated with better prognosis, while a high expression of PRKAB2 (P=0.003) was associated with poorer prognosis, suggesting that these 8 genes could be potential prognosis biomarkers for breast cancer patients. This evidence concerns the gene SIRAL2 and breast carcinoma.